-
1
-
-
0023121401
-
Cholesterol and mortality: 30 years follow-up from the Framingham study
-
1. Anderson KM, Castelli WP, Levy D. Cholesterol and mortality: 30 years follow-up from the Framingham study. JAMA 1987; 257: 2176-80
-
(1987)
JAMA
, vol.257
, pp. 2176-2180
-
-
Anderson, K.M.1
Castelli, W.P.2
Levy, D.3
-
2
-
-
0027243348
-
Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
-
2. Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993; 269: 3015-23
-
(1993)
JAMA
, vol.269
, pp. 3015-3023
-
-
-
3
-
-
0027987849
-
Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
-
3. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9
-
(1994)
Lancet
, vol.344
, pp. 1383-1389
-
-
-
4
-
-
0342981862
-
The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
-
4. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-9
-
(1996)
N Engl J Med
, vol.335
, pp. 1001-1009
-
-
Sacks, F.M.1
Pfeffer, M.A.2
Moye, L.A.3
-
5
-
-
0031030620
-
The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts
-
Post Coronary Artery Bypass Graft Trial Investigators
-
5. Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med 1997; 336 (3): 153-62
-
(1997)
N Engl J Med
, vol.336
, Issue.3
, pp. 153-162
-
-
-
6
-
-
0028883828
-
Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
-
6. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333 (20): 1301-7
-
(1995)
N Engl J Med
, vol.333
, Issue.20
, pp. 1301-1307
-
-
Shepherd, J.1
Cobbe, S.M.2
Ford, I.3
-
7
-
-
0032572086
-
Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS
-
7. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 1998; 279 (20): 1615-22
-
(1998)
JAMA
, vol.279
, Issue.20
, pp. 1615-1622
-
-
Downs, J.R.1
Clearfield, M.2
Weis, S.3
-
8
-
-
0032487931
-
Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
-
8. Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339 (19): 1349-57
-
(1998)
N Engl J Med
, vol.339
, Issue.19
, pp. 1349-1357
-
-
-
9
-
-
0022549920
-
A receptor-mediated pathway for cholesterol homeostasis
-
9. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science 1986; 232: 34-47
-
(1986)
Science
, vol.232
, pp. 34-47
-
-
Brown, M.S.1
Goldstein, J.L.2
-
10
-
-
0025120211
-
Regulation of the mevalonate pathway
-
10. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990; 343: 425-30
-
(1990)
Nature
, vol.343
, pp. 425-430
-
-
Goldstein, J.L.1
Brown, M.S.2
-
11
-
-
0029957678
-
Clinical pharmacokinetics of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors
-
11. Desager JP, Horsmans Y. Clinical pharmacokinetics of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. Clin Pharmacokinet 1996; 31: 348-71
-
(1996)
Clin Pharmacokinet
, vol.31
, pp. 348-371
-
-
Desager, J.P.1
Horsmans, Y.2
-
12
-
-
0030953045
-
Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors: Similarities and differences
-
12. Lennernas H, Fager G. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors: similarities and differences. Clin Pharmacokinet 1997; 32: 403-25
-
(1997)
Clin Pharmacokinet
, vol.32
, pp. 403-425
-
-
Lennernas, H.1
Fager, G.2
-
13
-
-
0027403267
-
Effect of fluvastatin sodium (XU62-320), a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on the induction of low-density lipoprotein receptor in HepG2 cells
-
13. Hayashi K, Kurokawa J, Nomura S, et al. Effect of fluvastatin sodium (XU62-320), a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on the induction of low-density lipoprotein receptor in HepG2 cells. Biochim Biophys Acta 1993; 1167: 223-5
-
(1993)
Biochim Biophys Acta
, vol.1167
, pp. 223-225
-
-
Hayashi, K.1
Kurokawa, J.2
Nomura, S.3
-
14
-
-
0032572043
-
Anti-atherothrombotic properties of statins
-
14. Rosenson RS, Tangney C. Anti-atherothrombotic properties of statins. JAMA 1998; 279: 1643-50
-
(1998)
JAMA
, vol.279
, pp. 1643-1650
-
-
Rosenson, R.S.1
Tangney, C.2
-
15
-
-
0032805692
-
New insights into the pharmacodynamic and pharmacokinetic properties of statins
-
15. Corsini A, Bellosta S, Baetta R, et al. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther 1999; 84: 413-28
-
(1999)
Pharmacol Ther
, vol.84
, pp. 413-428
-
-
Corsini, A.1
Bellosta, S.2
Baetta, R.3
-
16
-
-
0031781834
-
Direct vascular effects of HMG-CoA reductase inhibitors
-
16. Bellosta S, Bernini F, Ferri N, et al. Direct vascular effects of HMG-CoA reductase inhibitors. Atherosclerosis 1998; 137 Suppl.: S101-9
-
(1998)
Atherosclerosis
, vol.137
, Issue.SUPPL.
-
-
Bellosta, S.1
Bernini, F.2
Ferri, N.3
-
17
-
-
0029116986
-
HMG-CoA reductase inhibitors reduce acetyl LDL endocytosis in mouse peritoneal macrophages
-
17. Bemini F, Scurati N, Bonfadini G, et al. HMG-CoA reductase inhibitors reduce acetyl LDL endocytosis in mouse peritoneal macrophages. Arterioscler Thromb Vase Biol 1995; 15: 1352-8
-
(1995)
Arterioscler Thromb Vase Biol
, vol.15
, pp. 1352-1358
-
-
Bemini, F.1
Scurati, N.2
Bonfadini, G.3
-
18
-
-
0027537289
-
HMG-CoA reductase inhibitors: In vivo effects on carotid intimal thickening in normocholesterolemic rabbits
-
18. Soma MR, Donetti E, Parolini C, et al. HMG-CoA reductase inhibitors: in vivo effects on carotid intimal thickening in normocholesterolemic rabbits. Arterioscler Thromb 1993; 13: 571-8
-
(1993)
Arterioscler Thromb
, vol.13
, pp. 571-578
-
-
Soma, M.R.1
Donetti, E.2
Parolini, C.3
-
19
-
-
0033987474
-
Fluvastatin suppresses atherosclerotic progression, mediated through its inhibitory effect on endothelial dysfunction, lipid peroxidation, and macrophage deposition
-
19. Bandoh T, Mitani H, Niihasi M, et al. Fluvastatin suppresses atherosclerotic progression, mediated through its inhibitory effect on endothelial dysfunction, lipid peroxidation, and macrophage deposition. J Cardiovasc Pharmacol 2000; 35: 136-44
-
(2000)
J Cardiovasc Pharmacol
, vol.35
, pp. 136-144
-
-
Bandoh, T.1
Mitani, H.2
Niihasi, M.3
-
20
-
-
0029903829
-
Inhibitory effects of fluvastatin, a new HMG-CoA reductase inhibitor, on the increase in vascular ACE activity in cholesterol-fed rabbits
-
20. Mitani H, Bandoh T, Ishikawa J, et al. Inhibitory effects of fluvastatin, a new HMG-CoA reductase inhibitor, on the increase in vascular ACE activity in cholesterol-fed rabbits. Br J Pharmacol 1996; 119: 1269-75
-
(1996)
Br J Pharmacol
, vol.119
, pp. 1269-1275
-
-
Mitani, H.1
Bandoh, T.2
Ishikawa, J.3
-
21
-
-
0029947184
-
Fluvastatin: A review of its pharmacology and use in the management of hypercholestcrolaemia
-
21. Plosker GI, Wagstaff AJ. Fluvastatin: a review of its pharmacology and use in the management of hypercholestcrolaemia. Drugs 1996; 51: 433-59
-
(1996)
Drugs
, vol.51
, pp. 433-459
-
-
Plosker, G.I.1
Wagstaff, A.J.2
-
22
-
-
0028096810
-
A review of clinical trials comparing HMG-CoA reductase inhibitors
-
22. Illingworth DR, Tobert JA. A review of clinical trials comparing HMG-CoA reductase inhibitors. Clin Ther 1994; 16; 366-85
-
(1994)
Clin Ther
, vol.16
, pp. 366-385
-
-
Illingworth, D.R.1
Tobert, J.A.2
-
23
-
-
0032891783
-
Fluvastatin: A review of its use in lipid disorders
-
23. Langtry HD, Markham A. Fluvastatin: a review of its use in lipid disorders. Drugs 1999; 57: 583-606
-
(1999)
Drugs
, vol.57
, pp. 583-606
-
-
Langtry, H.D.1
Markham, A.2
-
24
-
-
0025763203
-
Effects of fluvastatin (XU62-320), an HMG-CoA reductase inhibitor, on the distribution and composition of low density lipoprotein subspecies in humans
-
24. Yuan JN, Tsai MY, Hegland J, et al. Effects of fluvastatin (XU62-320), an HMG-CoA reductase inhibitor, on the distribution and composition of low density lipoprotein subspecies in humans. Atherosclerosis 1991; 87: 147-57
-
(1991)
Atherosclerosis
, vol.87
, pp. 147-157
-
-
Yuan, J.N.1
Tsai, M.Y.2
Hegland, J.3
-
25
-
-
0032904753
-
A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty: Final results of the fluvastatin angiographic restenosis (FLARE) trial
-
25. Serruys PW, Foley DP, Jackson G, et al. A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty: final results of the fluvastatin angiographic restenosis (FLARE) trial. Eur Heart J 1998; 20: 58-69
-
(1998)
Eur Heart J
, vol.20
, pp. 58-69
-
-
Serruys, P.W.1
Foley, D.P.2
Jackson, G.3
-
26
-
-
0030841001
-
Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (lipoprotein and coronary atherosclerosis study [LCAS])
-
26. Herd JA, Ballantyne CM, Farmer JA, et al. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (lipoprotein and coronary atherosclerosis study [LCAS]). Am J Cardiol 1997; 80: 278-86
-
(1997)
Am J Cardiol
, vol.80
, pp. 278-286
-
-
Herd, J.A.1
Ballantyne, C.M.2
Farmer, J.A.3
-
27
-
-
0033016149
-
The effect of fluvastatin on cardiac events in patients with symptomatic coronary artery disease during one year of treatment
-
27. Riegger G, Abletshauser C, Ludwig M, et al. The effect of fluvastatin on cardiac events in patients with symptomatic coronary artery disease during one year of treatment. Atherosclerosis 1999; 144: 263-70
-
(1999)
Atherosclerosis
, vol.144
, pp. 263-270
-
-
Riegger, G.1
Abletshauser, C.2
Ludwig, M.3
-
28
-
-
0025794258
-
HMG-CoA reductase inhibitors: An exciting development in the treatment of hyperlipoproteinemia
-
28. Kathawala FG, HMG-CoA reductase inhibitors: an exciting development in the treatment of hyperlipoproteinemia. Med Res Rev 1991; 11: 121-46
-
(1991)
Med Res Rev
, vol.11
, pp. 121-146
-
-
Kathawala, F.G.1
-
29
-
-
0026694388
-
Pharmacokinetics of fluvastatin after single and multiple doses in normal volunteers
-
29. Tse FL, Jaffe JM, Troendle A. Pharmacokinetics of fluvastatin after single and multiple doses in normal volunteers. J Clin Pharmacol 1992; 32: 630-8
-
(1992)
J Clin Pharmacol
, vol.32
, pp. 630-638
-
-
Tse, F.L.1
Jaffe, J.M.2
Troendle, A.3
-
30
-
-
0029804297
-
Jejunal permeability and hepatic extraction of fluvastatin in humans
-
30. Lindahl A, Sandstrom R, Ungell AL, et al. Jejunal permeability and hepatic extraction of fluvastatin in humans. Clin Pharmacol Ther 1996; 60: 493-503
-
(1996)
Clin Pharmacol Ther
, vol.60
, pp. 493-503
-
-
Lindahl, A.1
Sandstrom, R.2
Ungell, A.L.3
-
31
-
-
0027146460
-
Pharmacokinetics of fluvastatin and specific drug interactions
-
Suppl.
-
31. Smith HT, Jokubaitis LA, Troendle AJ, et al. Pharmacokinetics of fluvastatin and specific drug interactions. Am J Hypertens 1993; 6 Suppl.(IIPt 2): 375S-382S
-
(1993)
Am J Hypertens
, vol.6
, Issue.2 PART 2
-
-
Smith, H.T.1
Jokubaitis, L.A.2
Troendle, A.J.3
-
32
-
-
0031803373
-
Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin
-
32. Kivisto KT, Kantola T, Neuvonen PJ. Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. Br J Clin Pharmacol 1998; 46: 49-53
-
(1998)
Br J Clin Pharmacol
, vol.46
, pp. 49-53
-
-
Kivisto, K.T.1
Kantola, T.2
Neuvonen, P.J.3
-
33
-
-
0029962009
-
Clinical pharmacokinetics of fluvastatin with reference to other HMG-CoA reductase inhibitors
-
33. Appel S, Dingemanse J. Clinical pharmacokinetics of fluvastatin with reference to other HMG-CoA reductase inhibitors. Drugs Today 1996; 32 Suppl. A: 37-55
-
(1996)
Drugs Today
, Issue.32 SUPPL. A
, pp. 37-55
-
-
Appel, S.1
Dingemanse, J.2
-
34
-
-
0028846142
-
In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (±)-fluvastatin
-
34. Transon C, Leemann T, Vogt N, et al. In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (±)-fluvastatin. Clin Pharmacol Ther 1995; 58: 412-7
-
(1995)
Clin Pharmacol Ther
, vol.58
, pp. 412-417
-
-
Transon, C.1
Leemann, T.2
Vogt, N.3
-
35
-
-
0025344378
-
Cytochrome P450 isoenzymes, epoxide hydrolase and glutathione transferases in rat and human hepatic and extrahepatic tissues
-
35. De Waziers I, Cugnenc PH, Yang CS, et al. Cytochrome P450 isoenzymes, epoxide hydrolase and glutathione transferases in rat and human hepatic and extrahepatic tissues. J Pharmacol Exp Ther 1990; 253: 387-94
-
(1990)
J Pharmacol Exp Ther
, vol.253
, pp. 387-394
-
-
De Waziers, I.1
Cugnenc, P.H.2
Yang, C.S.3
-
36
-
-
0025076205
-
Disposition of fluvastatin, an inhibitor of HMG-CoA reductase, in mouse, rat, dog, and monkey
-
36. Tse FLS, Smith HT, Ballard FH, et al. Disposition of fluvastatin, an inhibitor of HMG-CoA reductase, in mouse, rat, dog, and monkey. Biopharm Drug Dispos 1990; 11: 519-31
-
(1990)
Biopharm Drug Dispos
, vol.11
, pp. 519-531
-
-
Tse, F.L.S.1
Smith, H.T.2
Ballard, F.H.3
-
37
-
-
0027379402
-
Binding of fluvastatin to blood cells and plasma proteins
-
37. Tse FL, Nickerson DF. Yardley WS. Binding of fluvastatin to blood cells and plasma proteins. J Pharm Sci 1993; 82: 942-7
-
(1993)
J Pharm Sci
, vol.82
, pp. 942-947
-
-
Tse, F.L.1
Nickerson, D.F.2
Yardley, W.S.3
-
38
-
-
0027464373
-
Comparison of fluvastatin and lovastatin blood-brain barrier transfer using in vitro and in vivo methods
-
38. Guillot F, Misslin P, Lemaire M. Comparison of fluvastatin and lovastatin blood-brain barrier transfer using in vitro and in vivo methods. J Cardiovasc Pharmacol 1993; 21: 339-46
-
(1993)
J Cardiovasc Pharmacol
, vol.21
, pp. 339-346
-
-
Guillot, F.1
Misslin, P.2
Lemaire, M.3
-
39
-
-
0026596619
-
Absorption and disposition of fluvastatin, an inhibitor of HMG-CoA reductase in the rabbit
-
39. Tse FLS, Labbadia D. Absorption and disposition of fluvastatin, an inhibitor of HMG-CoA reductase in the rabbit, Biopharm Drug Dispos 1992; 13: 285-94
-
(1992)
Biopharm Drug Dispos
, vol.13
, pp. 285-294
-
-
Tse, F.L.S.1
Labbadia, D.2
-
40
-
-
0032937343
-
The 3-hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitor fluvastatin: Effect on human cytochrome P-450 and implications for metabolic drug interactions
-
40. Fischer V, Johanson L, Heitz F, et al. The 3-hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitor fluvastatin: effect on human cytochrome P-450 and implications for metabolic drug interactions. Drug Metab Dispos 1999; 27: 410-6
-
(1999)
Drug Metab Dispos
, vol.27
, pp. 410-416
-
-
Fischer, V.1
Johanson, L.2
Heitz, F.3
-
41
-
-
0030004755
-
In vitro comparative inhibition profiles of major human drug metabolizing cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors
-
41. Transon C, Leeman T, Dayer P. In vitro comparative inhibition profiles of major human drug metabolizing cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors. Eur J Clin Pharmacol 1996; 50: 209-15
-
(1996)
Eur J Clin Pharmacol
, vol.50
, pp. 209-215
-
-
Transon, C.1
Leeman, T.2
Dayer, P.3
-
42
-
-
0027296957
-
Biotransformation of fluvastatin sodium in humans
-
42. Dain JG, Fu E, Gorski J, et al. Biotransformation of fluvastatin sodium in humans. Drug Metab Dispos 1993; 21: 567-72
-
(1993)
Drug Metab Dispos
, vol.21
, pp. 567-572
-
-
Dain, J.G.1
Fu, E.2
Gorski, J.3
-
43
-
-
33646196523
-
Lidocaine
-
Evans WE, Schentag JJ, Jusko WJ, editors. Vancouver (WA): Applied Therapeutics
-
43. Pieper JA, Johnson KE. Lidocaine. In: Evans WE, Schentag JJ, Jusko WJ, editors. Applied pharmacokinetics: principles of therapeutic drug monitoring. 3rd ed. Vancouver (WA): Applied Therapeutics, 1992: 21.1-21.37
-
(1992)
Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring. 3rd Ed.
, pp. 211-2137
-
-
Pieper, J.A.1
Johnson, K.E.2
-
44
-
-
0028334550
-
Clinical implications of the biopharmaceutical properties of fluvastatin
-
44. Deslypere JP. Clinical implications of the biopharmaceutical properties of fluvastatin. Am J Cardiol 1994; 73: 12D-17D
-
(1994)
Am J Cardiol
, vol.73
-
-
Deslypere, J.P.1
-
45
-
-
0029008232
-
Fluvatatin for dyslipoproteinemia with or without concomitant chronic renal insufficiency
-
45. Lintott CJ, Scott RS, Bremer JM, et al. Fluvatatin for dyslipoproteinemia with or without concomitant chronic renal insufficiency. Am J Cardiol 1995; 76 (2): 97A-101A
-
(1995)
Am J Cardiol
, vol.76
, Issue.2
-
-
Lintott, C.J.1
Scott, R.S.2
Bremer, J.M.3
-
46
-
-
0028282809
-
Fluvastatin administration at bed-time versus with the evening meal: A multicenter comparison of bioavailability, safety, and efficacy
-
46. Dujovne CA, Davidson MH, Fluvastatin administration at bed-time versus with the evening meal: a multicenter comparison of bioavailability, safety, and efficacy. Am J Med 1994; 96 Suppl. 6A: 37S-40S
-
(1994)
Am J Med
, vol.96
, Issue.SUPPL. 6A
-
-
Dujovne, C.A.1
Davidson, M.H.2
-
47
-
-
0029025024
-
Effects of alcohol consumption on pharmacokinetics, efficacy, and safety of fluvastatin
-
47. Smit JW, Wijnne HJ, Schobben F, et al. Effects of alcohol consumption on pharmacokinetics, efficacy, and safety of fluvastatin. Am J Cardiol 1995; 76 (2): 89A-96A
-
(1995)
Am J Cardiol
, vol.76
, Issue.2
-
-
Smit, J.W.1
Wijnne, H.J.2
Schobben, F.3
-
48
-
-
0027755177
-
Efficacy and safety of high dose fluvastatin in patients with familial hypercholesterolemia
-
48. Leitersdorf E, Eisenberg S, Eliav G, et al. Efficacy and safety of high dose fluvastatin in patients with familial hypercholesterolemia. Eur J Clin Pharmacol 1993; 45: 513-8
-
(1993)
Eur J Clin Pharmacol
, vol.45
, pp. 513-518
-
-
Leitersdorf, E.1
Eisenberg, S.2
Eliav, O.3
-
49
-
-
0028209748
-
Low-dose combined therapy with fluvastatin and cholestyramine in hyperlipidemic patients
-
49. Sprecher DL, Abrams J, Allen JW, et al. Low-dose combined therapy with fluvastatin and cholestyramine in hyperlipidemic patients. Ann Intern Med 1994; 120: 537-43
-
(1994)
Ann Intern Med
, vol.120
, pp. 537-543
-
-
Sprecher, D.L.1
Abrams, J.2
Allen, J.W.3
-
50
-
-
0029704073
-
Fluvastatin in combination with other lipid-lowering agents
-
50. Jokubaitis L. Fluvastatin in combination with other lipid-lowering agents. Br J Clin Pract 1996; 77 Suppl. A: 28-32
-
(1996)
Br J Clin Pract
, vol.77
, Issue.SUPPL. A
, pp. 28-32
-
-
Jokubaitis, L.1
-
51
-
-
0028291040
-
Fluvastatin efficacy and tolerability in comparison and in combination with cholestyramine
-
51. Hagen E, Istad H, Bodd E, et al, Fluvastatin efficacy and tolerability in comparison and in combination with cholestyramine. Eur J Clin Pharmacol 1994; 46: 445-9
-
(1994)
Eur J Clin Pharmacol
, vol.46
, pp. 445-449
-
-
Hagen, E.1
Istad, H.2
Bodd, E.3
-
52
-
-
0028200059
-
Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase
-
52. Blum CB. Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Am J Cardiol 1994; 73: 3D-11D
-
(1994)
Am J Cardiol
, vol.73
-
-
Blum, C.B.1
-
53
-
-
0028149505
-
The pharmacology of fluvastatin, a new HMG-CoA reductase inhibitor
-
53. Garnett WR. The pharmacology of fluvastatin, a new HMG-CoA reductase inhibitor. Clin Cardiol 1994; 17 Suppl. IV: 3-10
-
(1994)
Clin Cardiol
, vol.17
, Issue.SUPPL. IV
, pp. 3-10
-
-
Garnett, W.R.1
-
54
-
-
0029166810
-
Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors
-
54. Garnett WR. Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors. Am J Health-Syst Pharm 1995; 52: 1639-45
-
(1995)
Am J Health-syst Pharm
, vol.52
, pp. 1639-1645
-
-
Garnett, W.R.1
-
55
-
-
0000329442
-
Effects of erythromycin on plasma fluvastatin levels: A pharmacokinetic study
-
55. Aberg J, Eriksson U, Fager G. Effects of erythromycin on plasma fluvastatin levels: a pharmacokinetic study [abstract]. A therosclerosis 1997; 134: 118A
-
(1997)
Atherosclerosis
, vol.134
-
-
Aberg, J.1
Eriksson, U.2
Fager, G.3
-
56
-
-
0032905659
-
The effects of fluvastatin, a CYP2C9 inhibitor, on losartan pharmacokinetics in healthy volunteers
-
56. Meadowcroft AM, Williamson KM, Patterson JH, et al. The effects of fluvastatin, a CYP2C9 inhibitor, on losartan pharmacokinetics in healthy volunteers. J Clin Pharmacol 1999; 39: 418-24
-
(1999)
J Clin Pharmacol
, vol.39
, pp. 418-424
-
-
Meadowcroft, A.M.1
Williamson, K.M.2
Patterson, J.H.3
-
57
-
-
0029042639
-
Lack of interaction between fluvastatin and oral hypoglycemic agents in healthy subjects and in patients with non-insulin dependent diabetes mellitus
-
57. Appel S, Rufenacht T, Kalafsky G, et al. Lack of interaction between fluvastatin and oral hypoglycemic agents in healthy subjects and in patients with non-insulin dependent diabetes mellitus. Am J Cardiol 1995; 76 (2): 29A-32A
-
(1995)
Am J Cardiol
, vol.76
, Issue.2
-
-
Appel, S.1
Rufenacht, T.2
Kalafsky, G.3
-
58
-
-
0028952010
-
The interaction of fluvastatin and cyclosporine A in renal transplant patients
-
58. Li PK, Mak TW, Wang AY, et al. The interaction of fluvastatin and cyclosporine A in renal transplant patients. Int J Clin Pharmacol Ther 1995; 33: 246-8
-
(1995)
Int J Clin Pharmacol Ther
, vol.33
, pp. 246-248
-
-
Li, P.K.1
Mak, T.W.2
Wang, A.Y.3
-
59
-
-
0029057971
-
Effect of fluvastatin for safely lowering atherogenic lipids in renal transplant patients receiving cyclosporine
-
59. Holdaas H, Hartmann A, Strenstrom J, et al. Effect of fluvastatin for safely lowering atherogenic lipids in renal transplant patients receiving cyclosporine. Am J Cardiol 1995; 76: 102A-5A
-
(1995)
Am J Cardiol
, vol.76
-
-
Holdaas, H.1
Hartmann, A.2
Strenstrom, J.3
-
60
-
-
0033392760
-
Fluvastatin in combination with cyclosporine in renal transplant recipients: A review of clinical safety and experience
-
60. Jardine A, Holdaas H. Fluvastatin in combination with cyclosporine in renal transplant recipients: a review of clinical safety and experience. J Clin Pharm Ther 1999; 24: 397-408
-
(1999)
J Clin Pharm Ther
, vol.24
, pp. 397-408
-
-
Jardine, A.1
Holdaas, H.2
-
61
-
-
0028766704
-
Pharmacokinetic effects of fluvastatin in patients chronically receiving digoxin
-
61. Garnett WR, Venitz J, Wilkens RC, et al. Pharmacokinetic effects of fluvastatin in patients chronically receiving digoxin. Am J Med 1994; 96 (6A): 84S-86S
-
(1994)
Am J Med
, vol.96
, Issue.6 A
-
-
Garnett, W.R.1
Venitz, J.2
Wilkens, R.C.3
-
62
-
-
0030463459
-
Evaluation of fluvastatin in the treatment of hypercholesterolemia in renal transplant recipients taking cyclosporine
-
62. Goldberg R, Roth D. Evaluation of fluvastatin in the treatment of hypercholesterolemia in renal transplant recipients taking cyclosporine. Transplantation 1996; 62: 1559-64
-
(1996)
Transplantation
, vol.62
, pp. 1559-1564
-
-
Goldberg, R.1
Roth, D.2
-
63
-
-
0031892332
-
Effects of erythromycin or rifampin on losartan pharmacokinetics in healthy volunteers
-
63. Williamson KM. Patterson JH, McQueen RH, et al. Effects of erythromycin or rifampin on losartan pharmacokinetics in healthy volunteers. Clin Pharmacol Ther 1998; 63: 316-23
-
(1998)
Clin Pharmacol Ther
, vol.63
, pp. 316-323
-
-
Williamson, K.M.1
Patterson, J.H.2
McQueen, R.H.3
-
64
-
-
0031736655
-
Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: Are the statins mechanistically similar?
-
64. Christians U, Jacobsen W, Floren LC, Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar? Pharmacol Ther 1998; 80: 1-34
-
(1998)
Pharmacol Ther
, vol.80
, pp. 1-34
-
-
Christians, U.1
Jacobsen, W.2
Floren, L.C.3
-
65
-
-
0026459449
-
Transport of digoxin by human P-glycoprotein expressed in a porcine kidney epithelial cell line (LLC-PK1)
-
65. Tanigawara Y, Okamura N, Hirai M, et al. Transport of digoxin by human P-glycoprotein expressed in a porcine kidney epithelial cell line (LLC-PK1). J Pharmacol ExpTher 1992; 263: 840-5
-
(1992)
J Pharmacol Exp Ther
, vol.263
, pp. 840-845
-
-
Tanigawara, Y.1
Okamura, N.2
Hirai, M.3
-
66
-
-
9044245300
-
Inhibition of the intestinal digoxin absorption and exsorption by quinidine
-
66. Su S, Huang J. Inhibition of the intestinal digoxin absorption and exsorption by quinidine. Drug Metab Dispos 1996; 24: 142-7
-
(1996)
Drug Metab Dispos
, vol.24
, pp. 142-147
-
-
Su, S.1
Huang, J.2
-
67
-
-
0033328139
-
The contribution of p-glycoprotein to pharmacokinetic drug-drug interactions
-
67. Yu DK. The contribution of p-glycoprotein to pharmacokinetic drug-drug interactions. J Clin Pharmacol 1999; 39: 1203-11
-
(1999)
J Clin Pharmacol
, vol.39
, pp. 1203-1211
-
-
Yu, D.K.1
-
68
-
-
0033678688
-
Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal p-glycoprotein-mediated secretion
-
68. Boyd RA, Stem RH, Stewart BH, Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal p-glycoprotein-mediated secretion. J Clin Pharmacol 2000; 40: 91-8
-
(2000)
J Clin Pharmacol
, vol.40
, pp. 91-98
-
-
Boyd, R.A.1
Stem, R.H.2
Stewart, B.H.3
-
69
-
-
0031871365
-
Concentration and region-dependent intestinal permeability of fluvastatin in the rat
-
69. Lindahl A, Sandstrom R, Ungell AL, et al. Concentration and region-dependent intestinal permeability of fluvastatin in thé rat. J Pharm Pharmacol 1998; 50: 737-44
-
(1998)
J Pharm Pharmacol
, vol.50
, pp. 737-744
-
-
Lindahl, A.1
Sandstrom, R.2
Ungell, A.L.3
-
70
-
-
0027739383
-
A major role for cytochrome P450TB (CYP2C9 subfamily) in the actions of nonsteroidal antiinflammatory drugs
-
70. Leeman T, Transon C, Bonnabry P, et al. A major role for cytochrome P450TB (CYP2C9 subfamily) in the actions of nonsteroidal antiinflammatory drugs. Drugs Exp Clin Res 1993; 19: 189-95
-
(1993)
Drugs Exp Clin Res
, vol.19
, pp. 189-195
-
-
Leeman, T.1
Transon, C.2
Bonnabry, P.3
-
71
-
-
0030935086
-
Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions
-
71. Bertz RJ, Granneman GR. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 1997; 32 (3): 210-58
-
(1997)
Clin Pharmacokinet
, vol.32
, Issue.3
, pp. 210-258
-
-
Bertz, R.J.1
Granneman, G.R.2
-
72
-
-
0000468588
-
Pharmacokinetic and pharmacodynamic interactions of fluvastatin and their therapeutic implications
-
72. Appel S, Dingemanse J. Pharmacokinetic and pharmacodynamic interactions of fluvastatin and their therapeutic implications. Rev Contemp Pharmacother 1996: 7: 167-82
-
(1996)
Rev Contemp Pharmacother
, vol.7
, pp. 167-182
-
-
Appel, S.1
Dingemanse, J.2
-
73
-
-
0004920423
-
Potential warfarin-fluvastatin interaction
-
73. Kline SS, Harrell CC. Potential warfarin-fluvastatin interaction [letter]. Ann Pharmacother 1997; 31 (6): 79
-
(1997)
Ann Pharmacother
, vol.31
, Issue.6
, pp. 79
-
-
Kline, S.S.1
Harrell, C.C.2
-
74
-
-
0030460426
-
Potential interaction between warfarin and fluvastatin
-
74. Trilli LE, Kelley CL, Aspinall SI, et al. Potential interaction between warfarin and fluvastatin. Ann Pharmacother 1996; 30: 1399-402
-
(1996)
Ann Pharmacother
, vol.30
, pp. 1399-1402
-
-
Trilli, L.E.1
Kelley, C.L.2
Aspinall, S.I.3
-
75
-
-
0030724427
-
Effect of fluconazole on the pharmcokinetics of eprosartan and losartan in healthy male volunteers
-
75. Kazierad DJ. Martin DE, Blum RA, et al. Effect of fluconazole on the pharmcokinetics of eprosartan and losartan in healthy male volunteers. Clin Pharmacol Ther 1997; 62 (4): 417-25
-
(1997)
Clin Pharmacol Ther
, vol.62
, Issue.4
, pp. 417-425
-
-
Kazierad, D.J.1
Martin, D.E.2
Blum, R.A.3
-
76
-
-
0000938294
-
Inhibitory effect of fluconazole (FLC) and erythromycin (ERY) plus fluvastatin (FLV) on losartan (L) disposition in normal volunteers
-
76. Parnell K, Rodgers J, Graff D, et al. Inhibitory effect of fluconazole (FLC) and erythromycin (ERY) plus fluvastatin (FLV) on losartan (L) disposition in normal volunteers [abstract]. Clin Pharmacol Ther 2000; 67 (2): PII-25
-
(2000)
Clin Pharmacol Ther
, vol.67
, Issue.2
-
-
Parnell, K.1
Rodgers, J.2
Graff, D.3
|